Choice Properties REIT Stock (OTC: PPRQF)

Latest News for Choice Properties REIT Stock (OTC:PPRQF)

Choice Properties

Choice Properties Real Estate Investment Trust invests in commercial retail, industrial, mixed-use, and residential properties across Canada. The company's portfolio primarily consists of shopping centers anchored by supermarkets and stand-alone supermarkets. The properties are mostly located in Ontario and Quebec, followed by Alberta, Nova Scotia, British Columbia, and New Brunswick. Choice Properties generates the majority of its revenue from leasing properties to its tenants. The company's principal tenant, the large-format retailer Loblaw Companies, contributes the vast majority of the total rent.

News

Intraday Update

Markets

Movers

Trading Ideas

AAPL

ACGL

ACLLF

ADBE

ADSK

ADYYF

AEBZY

AGNC

ALLT

ALMFF

ALSWF

AMRU

ANCUF

ANSS

ASGTF

ASNB

ATLC

ATRC

ATZAF

AVMXF

AZPN

BABYF

BAESF

BAESY

BASI

BAYZF

BBSRF

BIOS

BKRKY

BMXMF

BRRZY

CABGY

CABJF

CAMT

CAPMF

CCXI

CELH

CFDB

CGEMY

CHGCY

CHGS

CHJI

CLGN

CLPBF

CNBI

COST

CPIVF

CPRT

CSII

CSLLY

CTXS

CVCO

CYRLY

DBOEF

DBOEY

DEAC

DREUF

ELEEF

ELRE

EMRAF

ENGIY

ENTG

EONGY

EPOKY

EPZM

Stocks That Hit 52-Week Highs On Tuesday

Movers & Shakers

General

AACS

AAON

AAUKF

ACDSF

ACIA

ACLS

AFFY

AFGC

AIQUY

AJMPF

AKAM

ALCO

ALFVY

ALLE

AMADY

AMAT

AMBC

AMED

AMIGF

AMRC

AMWD

ANSLY

AOMFF

AOMOY

APAM

APPF

ARBV

ARES

ASAZF

ASAZY

ASHTY

ASPN

ASYS

ATCMF

ATVI

AUDC

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

BANF

BATRA

BCPC

BCUCY

BEVFF

BF-A

BF-B

BHOOY

BLDP

BLSP

BMDPY

BORT

BPOP

BRK-A

BRK-B

Stocks That Hit 52-Week Highs On Friday

Choice Properties Real Estate Investment Trust

<p>Financial giants have made a conspicuous bearish move on Zoetis. Our analysis of options history for Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) revealed 10 unusual trades.</p>
<p>Delving into the details, we found 30% of traders were bullish, while 70% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $101,874, and 7 were calls, valued at $355,916.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $150.0 to $185.0 for Zoetis over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Zoetis's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Zoetis's whale trades within a strike price range from $150.0 to $185.0 in the last 30 days. </p>
<h3>Zoetis Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714497360_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$10.2</td>
<td>$9.4</td>
<td>$9.4</td>
<td>$155.00</td>
<td>$151.3K</td>
<td>4.1K</td>
<td style="text-align: right;">73</td>
</tr>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$11.9</td>
<td>$9.7</td>
<td>$9.8</td>
<td>$155.00</td>
<td>$44.1K</td>
<td>4.1K</td>
<td style="text-align: right;">63</td>
</tr>
<tr>
<td>ZTS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$29.6</td>
<td>$27.5</td>
<td>$27.5</td>
<td>$185.00</td>
<td>$44.0K</td>
<td>106</td>
<td style="text-align: right;">16</td>
</tr>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$4.1</td>
<td>$3.7</td>
<td>$4.0</td>
<td>$165.00</td>
<td>$43.2K</td>
<td>3.3K</td>
<td style="text-align: right;">202</td>
</tr>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$4.1</td>
<td>$3.9</td>
<td>$4.0</td>
<td>$165.00</td>
<td>$33.2K</td>
<td>3.3K</td>
<td style="text-align: right;">11</td>
</tr>
</tbody>
</table>
</p>
<h3>About Zoetis</h3>
<p>Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.</p>
<h3>Present Market Standing of Zoetis</h3>
<ul>
<li>Currently trading with a volume of 1,502,526, the ZTS's price is down by -0.33%, now at $159.17. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 2 days.</li>
</ul>
<h3>What The Experts Say On Zoetis</h3>
<p>4 market experts have recently issued ratings for this stock, with a consensus target price of $200.0.</p>
<ul>
<li>Maintaining their stance, an analyst from Stifel continues to hold a Buy rating for Zoetis, targeting a price of $180. </li>
<li>An analyst from Piper Sandler downgraded its action to Overweight with a price target of $195. </li>
<li>Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Zoetis with a target price of $195. </li>
<li>Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Zoetis with a target price of $230. </li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Zoetis options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

This Is What Whales Are Betting On Zoetis

MSOS

AdvisorShares Trust AdvisorShares Pure US Cannabis ETF Resumes Trade

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Moderna</strong>.</p>
<p>Looking at options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) we detected 12 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 41% of the investors opened trades with bullish expectations and 41% with bearish.</p>
<p>From the overall spotted trades, 8 are puts, for a total amount of $322,262 and 4, calls, for a total amount of $261,450.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $50.0 to $120.0 for Moderna during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Moderna's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Moderna's substantial trades, within a strike price spectrum from $50.0 to $120.0 over the preceding 30 days.</p>
<h3>Moderna Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714497355_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$20.5</td>
<td>$20.0</td>
<td>$20.0</td>
<td>$115.00</td>
<td>$90.0K</td>
<td style="text-align: right;">579</td>
<td style="text-align: right;">45</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$40.95</td>
<td>$38.35</td>
<td>$40.25</td>
<td>$100.00</td>
<td>$80.5K</td>
<td style="text-align: right;">587</td>
<td style="text-align: right;">20</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$65.25</td>
<td>$63.75</td>
<td>$64.5</td>
<td>$50.00</td>
<td>$64.5K</td>
<td style="text-align: right;">54</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/03/24</td>
<td>$3.2</td>
<td>$2.58</td>
<td>$2.91</td>
<td>$109.00</td>
<td>$58.1K</td>
<td style="text-align: right;">270</td>
<td style="text-align: right;">212</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/10/24</td>
<td>$4.1</td>
<td>$4.05</td>
<td>$4.1</td>
<td>$110.00</td>
<td>$52.0K</td>
<td style="text-align: right;">161</td>
<td style="text-align: right;">52</td>
</tr>
</tbody>
</table>
</p>
<h3>About Moderna</h3>
<p>Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.</p>
<h3>Where Is Moderna Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,451,086, with MRNA's price down by -0.95%, positioned at $110.56.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 2 days.</li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Moderna, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


MRNA

Smart Money Is Betting Big In MRNA Options

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Hershey</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HSY, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 14 uncommon options trades for Hershey.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 35% bullish and 50%, bearish.</p>
<p>Out of all of the special options we uncovered, 7 are puts, for a total amount of $856,040, and 7 are calls, for a total amount of $395,294.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $195.0 to $230.0 for Hershey over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Hershey stands at 415.7, with a total volume reaching 1,064.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Hershey, situated within the strike price corridor from $195.0 to $230.0, throughout the last 30 days.</p>
<h3>Hershey Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714497350_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HSY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$24.3</td>
<td>$23.2</td>
<td>$24.3</td>
<td>$220.00</td>
<td>$243.0K</td>
<td style="text-align: right;">21</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>HSY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$24.2</td>
<td>$24.1</td>
<td>$24.2</td>
<td>$220.00</td>
<td>$193.6K</td>
<td style="text-align: right;">21</td>
<td style="text-align: right;">180</td>
</tr>
<tr>
<td>HSY</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$24.4</td>
<td>$21.1</td>
<td>$22.82</td>
<td>$210.00</td>
<td>$171.1K</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>HSY</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$18.4</td>
<td>$15.8</td>
<td>$17.18</td>
<td>$200.00</td>
<td>$128.8K</td>
<td style="text-align: right;">12</td>
<td style="text-align: right;">75</td>
</tr>
<tr>
<td>HSY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$7.1</td>
<td>$5.3</td>
<td>$6.7</td>
<td>$220.00</td>
<td>$93.8K</td>
<td style="text-align: right;">16</td>
<td style="text-align: right;">350</td>
</tr>
</tbody>
</table>
</p>
<h3>About Hershey</h3>
<p>Hershey is a leading confectionery manufacturer in the us (around a $25 billion market), controlling around 36% of the domestic chocolate space (per Euromonitor). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the us, including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix, Pirate Brands, and Dot's Pretzels over the past few years.</p>
<p>Having examined the options trading patterns of Hershey, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of Hershey</h3>
<ul>
<li>With a trading volume of 1,750,045, the price of HSY is up by 1.98%, reaching $196.28.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 3 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Hershey</h3>
<p>In the last month, 3 experts released ratings on this stock with an average target price of $192.66666666666666.</p>
<ul>
<li>Maintaining their stance, an analyst from Piper Sandler continues to hold a Neutral rating for Hershey, targeting a price of $179. </li>
<li>An analyst from Citigroup persists with their Neutral rating on Hershey, maintaining a target price of $199. </li>
<li>An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Hershey, which currently sits at a price target of $200. </li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Hershey options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Hershey Options Trading: A Deep Dive into Market Sentiment

IMCC

IM Cannabis Shares Halted On Circuit Breaker To The Upside, Stock Now Up 51.8%

Amplify ETF Trust Amplify Alternative Harvest ETF Shares Resume Trade

<p><strong>Lifeist Wellness Inc. </strong>(OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/LFSWF#OTCQB">LFSWF</a>) (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/LFST#TSXV">LFST</a>), a Toronto-based <a href="https://www.benzinga.com/cannabis" target="_blank" rel="noreferrer noopener">cannabis</a> and health-tech company, announced its financial results for the three months ended February 29, 2024.</p>
<p>The company reported <strong>net revenue of CA$4.9 million ($3.6 million)</strong>, a decrease from CA$5.9 million in the same period last year. Despite the revenue fall, the company demonstrated a stronger gross profit margin of 27% compared to 25% in Q1 2023. This improvement highlights Lifeist&#8217;s strategic shift towards premium, higher-margin products.</p>
<h4 class="wp-block-heading"><strong>Q1 2024 Financial Highlights</strong></h4>
<ul>
<li><strong>Revenue was CA$4.9 million </strong>compared to CA$5.9 million in Q1 2023.</li>
<li><strong>Net loss from continuing operations was CA$2.5 million, or (CA$0.004) per diluted share </strong>compared to a loss of $CA3.3 million, or (CA$0.007) per diluted share, in Q1 2023.</li>
<li><strong>Adjusted EBITDA loss improved to CA$2.1 million </strong>compared to the CA$3 million in the same quarter last year.</li>
<li><strong>Gross profit was CA$1.3 million</strong> compared to the CA$1.4 million from Q1 2023.</li>
</ul>
<p><em>Don&#8217;t miss the upcoming <a href="https://cannabismarketspotlight.com/" target="_blank" rel="noreferrer noopener"><strong>Benzinga Cannabis Market Spotlight</strong></a> on <strong>June 17 in New Jersey</strong>, where industry leaders, including top CEOs and investors, will gather to share invaluable insights. This event is your chance to delve into strategic discussions like those shaping Lifeist Wellness&#8217;s journey towards improved financial health and strategic growth.</em></p>
<h3 class="wp-block-heading"><strong>CEO's Perspective</strong></h3>
<p>"Our performance in the first quarter of 2024 reflects the challenges of operating in the present regulatory and economic landscape," said <strong>Meni Morim</strong>, CEO of Lifeist. "While our efforts to focus on premium, higher margin products and continued operational efficiencies have led to improvements in the bottom line, the quarter reflected a drop in revenue from a year ago. We are taking steps to address structural issues within our operations and will act on opportunities to increase revenue and drive toward profitability. The teams at CannMart, Aussie Vapes, and Mikra are working tirelessly to realize the goal of transforming Lifeist into a sustainable, diversified <a href="https://www.benzinga.com/markets/cannabis/23/09/34298044/discover-wellness-the-latest-in-cannabis-infused-beverages-gummies-redefining-tomorrow" target="_blank" rel="noreferrer noopener">wellness</a> company."</p>
<h3 class="wp-block-heading"><strong>Organizational Changes and Future Outlook</strong></h3>
<p>Amid financial adjustments, Lifeist announced the appointment of <strong>Joshua Hone</strong> as the CFO, effective April 30, 2024. Hone, succeeding interim CFO <strong>John Sinclair</strong>, is expected to drive further financial improvements and sustainable profitability for the company. Sinclair will continue to serve on the board of directors and chair the audit committee.</p>
<p><strong>LFSWF Price Action</strong><br />LFSWF's shares were trading 0.000% lower/higher at $0.00 per share at the time of this writing around 2:30 PM ET Friday.</p>
<p><strong>Related News</strong></p>
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/04/38048846/lifeist-reports-highest-quarterly-gross-profit-in-history-continues-to-diversify-its-wellness-bu" target="_blank" rel="noreferrer noopener">Lifeist Reports Highest Quarterly Gross Profit In History, Continues To Diversify Its Wellness Business</a></li>
<li><a href="https://www.benzinga.com/markets/cannabis/24/02/36913640/canadian-company-lifeist-says-farewell-to-cannabis-business-unit-turns-to-nutraceuticals" target="_blank" rel="noreferrer noopener">Canadian Company Lifeist Says Farewell To Cannabis Business Unit, Turns To Nutraceuticals</a></li>
</ul>
<p><em>Photo: Courtesy of iQoncept via Shutterstock.</em></p>


Cannabis

Earnings

LFST

LFSWF

TSXV:LFST

Revenue Down, Margins Up: Lifeist's Q1 Financial Results Show Focus On Premium Products Curbed Revenue Drop

Amplify ETF Trust Amplify Alternative Harvest ETF Shares Halted On Circuit Breaker To The Upside, Stock Now Up 8.62%

<p>RBC Capital  analyst Matthew McKellar   maintains Clearwater Paper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLW#NYSE">CLW</a>) with a Sector Perform and raises the price target from $41 to $42.</p>


Price Target

Analyst Ratings

RBC Capital Maintains Sector Perform on Clearwater Paper, Raises Price Target to $42

<p>At the recent <strong><a href="https://www.benzinga.com/events/">Benzinga Cannabis Capital Conference</a></strong>, <strong>Dreka Gates</strong>, founder of <strong><a href="https://www.benzinga.com/markets/cannabis/24/04/38223982/dreka-gates-flips-script-from-beats-to-buds">Love&#8217;s Harvest</a></strong>, shared insights into the significant connections formed at the event. </p>
<p>&#8220;I&#8217;ve just met five people right off the bat that I know we&#8217;re going to co-create and do some amazing things together,&#8221; Gates said, highlighting the conference&#8217;s role as a catalyst for meaningful industry relationships.</p>
<h1 class="wp-block-heading"><strong>A Day in the Life at Love&#8217;s Harvest&nbsp;</strong></h1>
<p>Gates, who was previously known for managing her husband Kevin Gates&#8217;s music career, delved into the daily operations of her cannabis business. </p>
<p>&#8220;It&#8217;s really just rewarding for me to see it from start to finish,&#8221; she said, emphasizing the satisfaction derived from customers&#8217; positive reactions in the dispensary. Gates enjoys overseeing the process from the initial plant stages to the final consumer interaction.</p>
<h1 class="wp-block-heading"><strong>Future Plans and Expansion&nbsp;</strong></h1>
<p>Looking ahead, Gates revealed plans for Love&#8217;s Harvest to become a vertically integrated operation within the next year. She is particularly excited about a forthcoming product line that will incorporate other beneficial plants and herbs with cannabis. &#8220;I am super happy about that,&#8221; Gates said, indicating her commitment to comprehensively enhancing wellness.</p>
<h1 class="wp-block-heading"><strong>The Transformative Impact of Cannabis</strong></h1>
<p>Gates spoke passionately about the transformative potential of cannabis, particularly in promoting wellness and alleviating chronic pain through various forms, such as topicals and tinctures. </p>
<p>&#8220;It&#8217;s about Love and wellness for everyone,&#8221; Gates said aiming to educate and redefine the public&#8217;s perception of cannabis users, moving beyond stigmatized stereotypes.</p>
<h1 class="wp-block-heading"><strong>Consumer Trends </strong></h1>
<p>Discussing current trends, Gates noted a growing consumer preference for food-inspired cannabis strains and rapid-release products in Mississippi. </p>
<p>&#8220;People want it to be, like the rapid release and the fast-acting that has been becoming very popular,&#8221; she observed, reflecting on the evolving demands of consumers seeking immediate effects from their cannabis products.</p>
<p>Her main panel discussion was a highlight for Gates, who appreciated the opportunity to interact with the audience and other panelists. </p>
<p>&#8220;It was amazing because we connected with the audience. Afterward, they all approached us and wanted to communicate with us,&#8221; Gates shared, stressing the value of industry events in fostering community and advancing understanding within the cannabis world.</p>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<p><em>Grow Your Cannabis business and raise capital at&nbsp;<a href="https://cannabismarketspotlight.com/" target="_blank" rel="noreferrer noopener">Benzinga's New Jersey Market Spotlight</a>&nbsp;on June 17. Network with key industry players, hear from the top operators, and close deals that will shape the future. Act now— spots are filling fast. Get your tickets&nbsp;<a href="https://cannabismarketspotlight.com/" target="_blank" rel="noreferrer noopener">here</a>.</em></p>
<p><em>Photo: Paul Smith, <a href="https://www.shutterstock.com/image-photo/los-angeles-usa-november-28-2023-2394302817">FeatureFlash</a>, Shutterst</em>ock</p>


Events

Exclusives

Interview

EXCLUSIVE: How Dreka Gates Transforms Cannabis Perceptions

WIIM

AKAN

CRON

LFLY

MAPS

SNDL

TLRY

Shares of cannabis stocks are trading higher following a report indicating the DEA is moving to reclassify marijuana as a less dangerous drug.

Macro Economic Events

Economics

RMAX

U.S. Treasury Secretary Yellen Says Home Market 'Almost Impossible' For First-Time Buyers

SGBX

Safe & Green Holdings shares are trading lower after the company announced a 1-for-20 reverse split.

<p>RBC Capital  analyst Sean Dodge   maintains Avid Bioservices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDMO#NASDAQ">CDMO</a>) with a Outperform and raises the price target from $7 to $8.</p>


CDMO

RBC Capital Maintains Outperform on Avid Bioservices, Raises Price Target to $8

GRWG

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

KERN

DEA Moving To Reclassify Marijuana As Less Dangerous Drug

<p>In a recent episode of &#8220;<a href="https://www.benzinga.com/personal-finance/24/04/38055969/new-mom-tells-dave-ramsey-her-husband-makes-950k-but-wont-let-her-stay-home-i-think-you-can-prob">The Ramsey Show,</a>&#8221; 59-year-old caller Laronda revealed she is saddled with $258,000 in student loans, sparking a discussion on the financial challenges older students face. The episode, titled &#8220;I&#8217;m 59 and Still Owe $258,000 In Student Loans!&#8221; captures the caller&#8217;s distress over her substantial debt.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong></strong><strong>If the United States had access to<a href="https://www.benzinga.com/money/public-hys-avgamerican"><strong> </strong><strong>today&#8217;s high-yield savings accounts rates</strong></a> in 2015, it wouldn&#8217;t need to save another penny.</strong></li>
<li><strong></strong><strong>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"><strong> </strong><strong>The percentage may shock you</strong></a>.</strong></li>
</ul>
<p>The gravity of Laronda's situation became evident as she explained her employment history and current job role. Despite having a master's degree in accounting, she is in a logistics role at Volvo Trucks, a field unrelated to her primary area of study. She works two jobs and is trying to make the debt "go away."</p>
<p>Ramsey, noting the $258,000 debt, asked about her degrees and questioned why she was earning only $60,000 per year with a master&#8217;s degree. She expressed frustration over the disconnect between her education and her job, highlighting a common issue: Her academic training did not adequately prepare her for the technological demands of modern accounting jobs, such as proficiency with software like SAP.</p>
<p>&#8220;These are disturbing numbers,&#8221; Ramsey said. &#8220;You have not monetized your knowledge base very well.&#8221;</p>
<p>Ramsey suggested that with her qualifications, Laronda should be earning significantly more — somewhere between $100,000 and $125,000 annually. He urged her to undergo some soul-searching to determine why her income was so low, suggesting that it likely stemmed from her attitude. </p>
<p><strong>Trending: Warren Buffett flipped his neighbor's $67,000 life savings into a $50 million fortune —<a href="https://www.benzinga.com/money/advisor-adv-warren-buffett"> <strong>How much is that worth today?</strong></a></strong></p>
<p>He also demystified modern accounting practices, saying, &#8220;You don't do accounting with calculators and haven't in decades. It's not rocket science; I can do it.&#8221;</p>
<p>Ramsey's co-host, George Kamel, chimed in, pointing out that <a href="https://www.benzinga.com/personal-finance/24/03/37588475/dave-ramsey-shares-he-went-bankrupt-and-lost-everything-years-ago-while-empathizing-with-caller-">bankruptcy isn&#8217;t an option</a> and suggesting she discuss financial contributions with her children to help alleviate the burden so she could eventually retire.</p>
<p>Ramsey emphasized the need for a better &#8220;shovel-to-hole ratio,&#8221; a metaphor highlighting the crucial role of increasing her income to manage her debt. His advice? &#8220;Live on nothing,&#8221; he said, advocating for cutting down all nonessential expenses. Any freed-up funds should be channeled toward aggressive debt repayment.</p>
<p>Ramsey believes Laronda can become debt-free within four years but with a stipulation.&nbsp;</p>
<p>&#8220;You need to learn to operate a computer,&#8221; he said. &#8220;You paid a lot for all this knowledge, and you&#8217;re not getting anything for it.&#8221;</p>
<p>While increasing income is beneficial, it&#8217;s not always a guaranteed solution. The job market for experienced accountants, particularly those without recent technological training, can be competitive. Laronda&#8217;s age could also be a factor in securing a higher-paying position.</p>
<p>Laronda might benefit from a multipronged approach. Upskilling in accounting software could open doors to better opportunities in her field. Exploring options for income-based repayment plans or loan forgiveness programs could also provide some relief. The best path forward will likely involve a combination of strategies tailored to her specific circumstances.</p>
<p><a href="https://www.benzinga.com/money/smartasset">Consulting a financial adviser</a> can be crucial for those planning for retirement. An adviser can evaluate your financial situation, help set realistic goals and tailor a plan that maximizes your investments. This personalized strategy ensures that your savings are efficiently working toward securing a comfortable retirement, allowing you to focus on living your best life.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"><strong> How do you compare</strong></a>?</strong></li>
<li><strong></strong><strong>The<a href="https://www.benzinga.com/money/public-hys-avgamerican"><strong> </strong><strong>shocking amount the average American would save by now</strong></a> if they started an account in 2010 with today&#8217;s high yield savings rates will make you run to open your own.</strong></li>
</ul>


Personal Finance

'I'm 59 And Still Owe $258,000 In Student Loans' — Dave Ramsey Caller Makes $60,000 A Year Working Two Jobs And Not Using Her Degrees

<p>DA Davidson  analyst Jeff Rulis   maintains Bank of Marin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRC#NASDAQ">BMRC</a>) with a Neutral and lowers the price target from $17 to $15.</p>


BMRC

DA Davidson Maintains Neutral on Bank of Marin, Lowers Price Target to $15

AdvisorShares Trust AdvisorShares Pure US Cannabis ETF Shares Halted On Circuit Breaker To The Upside, Stock Now Up 4.21%

<p>Truist Securities  analyst Gregory Fraser   maintains Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) with a Buy and lowers the price target from $10 to $8.</p>


XAIR

Truist Securities Maintains Buy on Beyond Air, Lowers Price Target to $8

<p>DA Davidson  analyst Manuel Navas   maintains Fulton Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULT#NASDAQ">FULT</a>) with a Neutral and raises the price target from $15 to $18.</p>


FULT

DA Davidson Maintains Neutral on Fulton Financial, Raises Price Target to $18

Choice Properties Reit (OTC) (TSE:CHP.UN) has released an update. Choice Properties REIT has reported a solid first quarter in 2024 with a 6.1% inc...

Choice Properties REIT Q1 Financial Performance

Choice Properties Real Estate Investment Trust reports Q1 results

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Latest News for Choice Properties REIT Stock (OTC:PPRQF)

Tuesday, January 21, 2020

Friday, January 17, 2020